Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  The Medicines Company    MDCO

THE MEDICINES COMPANY

(MDCO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Medicines : Shares Up 19% After Bloomberg Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2019 | 11:02am EST

By Michael Dabaie

Medicines Co. (MDCO) shares rose 19% to $69.83 Tuesday morning in heavier-than-average volume.

Bloomberg reported earlier that Medicines Co. has attracted takeover interest from suitors, including from Novartis AG, citing people familiar with the matter.

Novartis has been holding talks about a potential acquisition of the company, according to the people, Bloomberg reported. Novartis is conducting due diligence on the company, one of the people said, according to the Bloomberg report.

Officials from Medicines Co. and Novartis declined to comment.

Medicines Co. said Monday that the ORION-9 study of inclisiran in heterozygous familial hypercholesterolemia patients showed durable low-density lipoprotein cholesterol lowering with twice-yearly dosing.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS 0.04% 91.32 Delayed Quote.22.85%
THE MEDICINES COMPANY -0.05% 84.03 Delayed Quote.339.03%
This article is part of a news chaine.
Article 2 / 2
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THE MEDICINES COMPANY
12/02Monteverde & Associates PC Announces an Investigation of THE MEDICINES COMPAN..
PR
11/26WeissLaw LLP Investigates The Medicines Co.
PR
11/25World share markets rally on revived trade hopes; dollar gains
RE
11/25World share markets rally on revived trade hopes; dollar gains
RE
11/25THE MEDICINES COMPANY ALERT : Bragar Eagel & Squire, P.C. Investigates the Propo..
PR
11/25EUROPE : Transatlantic dealmaking sends European shares back to four-year peak
RE
11/25The Medicines Co. Shares Up 23% on Novartis Buyout Offer
DJ
11/25BLACK FRIDAY FRENZY : Tiffany buys LVMH, Charles Schwab buys TD Ameritrade, Nova..
11/25(MDCO) ALERT : Johnson Fistel Investigates Proposed Sale of The Medicines Compan..
PR
11/25ALNYLAM PHARMACEUTICALS : Announces 2020 Product and Pipeline Goals and Provides..
AQ
More news
Financials (USD)
Sales 2019 1,37 M
EBIT 2019 -208 M
Net income 2019 -261 M
Debt 2019 616 M
Yield 2019 -
P/E ratio 2019 -25,3x
P/E ratio 2020 -22,9x
EV / Sales2019 5 351x
EV / Sales2020 228x
Capitalization 6 718 M
Chart THE MEDICINES COMPANY
Duration : Period :
The Medicines Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE MEDICINES COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 80,64  $
Last Close Price 84,03  $
Spread / Highest target 13,1%
Spread / Average Target -4,04%
Spread / Lowest Target -40,5%
EPS Revisions
Managers
NameTitle
Clive A. Meanwell Chief Innovation Officer & Director
Mark Timney Chief Executive Officer & Director
Alexander John Denner Chairman
Christopher Visioli Chief Financial Officer & Treasurer
John C. Kelly Independent Director
Sector and Competitors